Skip to main content

What’s New in Acute Myeloid Leukemia (AML) Research?

Researchers continue to study the causes, diagnosis, and treatment of acute myeloid leukemia (AML) at many medical centers, university hospitals, and other institutions around the world.

Genetics of AML

There continues to be progress in understanding how normal bone marrow cells can develop into leukemia cells. It has become clear that there are many types of AML. Each type of AML might have different DNA (gene) changes that affect how it will progress and which treatments might be most helpful. Researchers continue to study how DNA changes specific to different AML types can help us understand how to best treat each person’s AML.

Detecting minimal residual disease

In recent years, highly sensitive tests have been developed to detect even the smallest amount of leukemia left after treatment (known as minimal residual disease, or MRD), even when there are so few leukemia cells left that they can’t be found by routine bone marrow tests.

Multiparameter flow-cytometry (MFC), quantitative polymerase chain reaction (qPCR), and next-generation sequencing (NGS) are tests that can be used to identify even very small numbers of AML cells in a sample. These tests are useful in determining how completely the treatment has destroyed the AML cells.

Studies are continuing on which test to use and how to best use the information from these tests. The presence of minimal residual disease affects a patient’s outlook, as well as if the patient will need further or more intensive treatment.

Improving treatment

Treatment for AML can be very effective for some people, but it doesn't cure everyone, and it can often cause serious or even life-threatening side effects. Studies are looking for more effective and safer treatments for AML. Questions remain on how to sequence and combine drugs approved to treat AML to best fight the disease.


Chemotherapy (chemo) is still the main treatment for most types of AML.

Researchers are looking for the most effective combination of chemo drugs that will also limit unwanted side effects. This is especially important for older patients who might not be able to tolerate the side effects of currently approved treatments for AML.

The effectiveness of chemo may be limited in some cases because the leukemia cells become resistant to it over time. Researchers are now looking at ways to prevent or reverse this resistance by using other drugs along with chemo. They are also looking at combining chemo with newer types of drugs to see if this might work better.

Stem cell transplants

Researchers continue to refine stem cell transplants to try to increase their effectiveness, reduce complications, and determine which patients are likely to be helped by this treatment. Many studies are trying to determine exactly when autologous, allogeneic, and mini-transplants might best be used.

Targeted therapy drugs

Chemo drugs can help many people with AML, but these drugs don’t always cure the disease. Newer targeted drugs that specifically attack some of the gene changes seen in AML cells have become an important part of treatment for some people. These drugs don't work the same way as standard chemotherapy drugs. Some examples include:

FLT3 inhibitors. In some people with AML, the leukemia cells have a change (mutation) in the FLT3 gene. Drugs called FLT3 inhibitors target AML cells with this gene change. FLT3 inhibitors such as midostaurin (Rydapt), quizartinib (Vanflyta),  and gilteritinib (Xospata) are now approved to treat people whose AML cells have an FLT3 mutation. Several other FLT3 inhibitors are now being studied as well..

IDH inhibitors. In some people with AML, the leukemia cells have a mutation in the IDH1 or IDH2 gene, which stops the cells from maturing properly. IDH inhibitors can help the leukemia cells mature into normal blood cells. Some of these drugs, such as enasidenib (Idhifa), olutasidenib (Rezlidhia), and ivosidenib (Tibsovo), are now approved to treat AML with certain IDH gene mutations. Several other IDH inhibitors are now being studied as well.

BCL-2 inhibitors. Some people with AML have leukemia cells that make too much of a protein called BCL-2. Leukemia cells that overexpress BCL-2 tend to be harder to kill with chemo drugs. BCL-2 inhibitors prevent the BCL-2 protein from working in cancer cells. Venetoclax (Venclexta) is a BCL-2 inhibitor that has been approved to treat AML with BCL-2 overexpression. Several other BCL-2 inhibitors are being studied as well. 

Immunotherapy drugs

Immunotherapy works to boost the body’s immune system to help fight off or destroy cancer cells.

Bispecific antibodies. A bispecific antibody consists of two antibodies that each attach to a different target, so that two cells can be brought close together. One antibody is usually designed to attach to a target on the leukemia cell, while the other is designed to attach to a target on an immune cell (for example, T cells). When the bispecific antibody brings the cancer cell and immune cell together, your immune system is alerted and starts to fight the cancer cell. Several bispecific antibodies are now being studied for use against AML.

Antibody-drug conjugates (ADC). An ADC is a drug that consist of two parts: an antibody designed to attach to a surface protein on cancer cells and a toxin meant to kill the cancer cells. When ADCs are injected into the body, they act like a homing device, bringing the drug directly to the cancer cells, which kills them. ADCs are already used to treat some types of cancer, and some ADCs are now being studied for use against AML.

Immune checkpoint inhibitors. An important part of the immune system is its ability to keep itself from attacking other normal cells in the body. To do this, it uses “checkpoint” proteins on immune cells that need to be turned on (or off) to start an immune response. Cancer cells sometimes use these checkpoints to avoid being attacked by the immune system. Drugs called immune checkpoint inhibitors (ICIs) target these checkpoints and are already used in many other cancers. They continue to be studied for use in AML, especially if combined with chemo or targeted therapy drugs.

Chimeric antigen receptor (CAR) T-cell therapy. For this therapy, immune cells called T cells are removed from the person’s blood and altered in the lab so they have specific substances (called chimeric antigen receptors, or CARs) that will help them attach to leukemia cells. The T cells are then grown in the lab and infused back into the person’s blood, where they can now seek out the leukemia cells and attack them.

This therapy has been shown to work in other types of blood cancers. However, it’s not yet clear if it will work against AML. Researchers are continuing to study how this therapy can be used to treat AML.



The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.


Bhansali RS, Pratz KW,  Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 16, 29 (2023).

Dekker SE,  Rhea D, Cayuela J-M , Arnhardt I,  Leonard J,  Heuser M. Using measurable residual disease to optimize management of AML, ALL, and chronic myeloid leukemia. DOI: 10.1200/EDBK_390010 American Society of Clinical Oncology. Educational Book 43 (June 13, 2023)

Kadia TM, Ravandi F, Cortes J, Kantarjian H. New drugs in acute myeloid leukemia. Ann Oncol. 2016;27(5):770-778.

Kebriaei P, de Lima M, Estey EH, Champlin R. Chapter 107: Management of Acute Leukemias. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2015.


Last Revised: September 19, 2023

American Cancer Society Emails

Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.